Please type a plus sign (+) inside this box →

PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	Continuation of 08/083,088
Filing Date	February 14, 2001
First Named Inventor	Peter M. Glazer
Group Art Unit	
Examiner Name	
Attorney Docket Number	YU 109 CON

Sheet 1 of 4

J1017 U.S. PTO 09/783338 02/14/01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	US Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office.[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		EP	0 266 099		Johns Hopkins University	05-04-1988		
		EP	0 375 408		Baylor College of Medicine	06-27-1990		

Examine Signature		Date Considered	10/19/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

[1] Unique citation designation number [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Continuation of 08/083,088
	Filing Date	February 14, 2001
	First Named Inventor	Peter M. Glazer
	Group Art Unit	
	Examiner Name	
Sheet 2 of 4	Attorney Docket Number	YU 109 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		BEAL, et al., "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation," *Science* 251:1360-1363 (1991).	
		BEAL, et al., "The Influence of Single Base Triplet Changes on the Stability of Pur-Pur-Pyr Triple Helix Determined by Affinity Cleaving," *Nuc. Acids Res.* 11:2773 (1992).	
		BLUME, et al., "Triple Helix Formation by Purine-Rich Oligonucleotides Targeted to the Human Dihydrofolate Reductase Promoter," *Nucleic Acids Rec.* 20:1777 (1992).	
		COONEY, "Site-Specific Oligonucleotide Binding Represses Transcription of the Human *c-myc* Gene in Vitro," *Science* 241:456 (1988).	
		DURLAND, "Binding of Triple Helix Forming Oligonucleotides to Sites in Gene Promoters," *Biochemistry* 30:9246 (1991).	
		DUVAL-VALENTIN, et al., "Specific Inhibition of Transcription by Triple Helix-Forming Oligonucleotides," *Proc. Natl. Acad. Sci. USA* 89:504 (1992).	
		FRANCOIS, "Sequence-Specific Recognition and Cleavage of Duplex DNA via Triple-Helix Formation by Oligonucleotides Covalently Linked to a Phenanthroline-Copper Chelate," *Proc. Natl. Acad. Sci. USA* 86:9702 (1989).	
		GASPARRO, et al., "Site-specific targeting of Psoralen Photoadducts with a Triple Helix-Forming Oligonucleotide: Characterization of Psoralen Monoadduct and Crosslink Formation," *Nucleic Acids Research*, 22(14):2845-2852 (1994).	
		GIOVANNANGELI, et al., "Oligodeoxynucleotide-directed photo-induced cross-linking of HIV proviral DNA via triple-helix formation," *Nucleic Acids Res.* 20:4275-4281 (1992).	
		GLAZER, et al., "Detection and Analysis of UV-induced Mutations in Mammalian Cell DNA Using A Phage Suttle Vector," *Proc. Natl. Acad. Sci.* 83:1041-1044 (1986).	

Examiner's Signature		Date Considered	10/19/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	Continuation of 08/083,088
Filing Date	February 14, 2001
First Named Inventor	Peter M. Glazer
Group Art Unit	
Examiner Name	
Attorney Docket Number	YU 109 CON

Sheet 3 of 4

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		GRIGORIEV, et al., "A Triple-Helix-Forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via Inhibition of NF κB Binding to Interleukin-2 Receptor α-Regulatory Sequence," *J. of Biological Chem.* 267:3389 (1992).	
		GRIGORIEV, et al., "Inhibition of Gene Expression by Triple Helix-directed DNA Cross-linking at Specific Sites," *Proceedings of the National Academy of Sciences of USA*, 90(8):3501-3505 (1993)	
		HAVRE, et al., "Targed Mutagenesis of DNA Using Triple Helix-forming Oligonucleotides Linked to Psoralen," *Proc. Natl. Acad. Sci. USA*, 90(16):7879-7883 (1993).	
		ITO, et al., "Sequence-Specific DNA Purification by Triplex Affinity Capture," *Proc. Natl. Acad. Sci. USA* 89:495 (1992).	
		LIN, et al., "Use of EDTA Derivatization to Characterize Interactions Between Oligodeoxyribonucleoside Methylphosphonates and Nucleic Acids," *Biochemistry* 28:1054 (1989).	
		MAHER, et al., "Analysis of Promoter-Specific Repression by Triple Helical DNA Complexes in a Eukarvotic Cell-Free Transcription System," *Biochemistry* 31:70 (1992).	
		MAHER, et al., *Science* 245:725 (1989).	
		MERGNY, et al., "Sequence Specificity in Triple-Helix Formation: Experimental and Theoretical Studies of the Effect of Mismatches on Triplex Stability," *Biochemistry* 30:9791 (1991).	
		MIRABELLI, et al., "In Vitro and in vivo pharmacologic activities of antisense oligonucleotides," *Anticancer Design* 6:647-661 (1991).	
		MOSER, et al., "Sequence-Specific Cleavage of Double Helical DNA by Triple Helix Formation," *Science* 238:645 (1987).	

Examiner's Signature		Date Considered	10/14/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-99)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Continuation of 08/083,088
	Filing Date	February 14, 2001
	First Named Inventor	Peter M. Glazer
	Group Art Unit	
	Examiner Name	
Sheet 4 of 4	Attorney Docket Number	YU 109 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		ORSON, et al., "Oligonucleotide Inhibition of IL2Rα mRNA Transcription by Promoter Region Collinear Triplexed Formation in Lymphocytes," *Nucleic Acids Res.* 19:3435 (1991).	
		PEI, "Site Specific Cleavage of Duplex DNA by a Semisynthetic Nuclease via Triple-Helix Formation," *Proc. Natl. Acad. Sci. USA* 87:9858 (1990).	
		PERROUAULT, et al., "Sequence-Specific Artificial Photo-induced Endonuclease Based on Triple Helix-Forming Oligonucleotides," *Nature* 344:358 (1990).	
		POSTEL, et al., "Evidence that a Triple-Forming Oligodeoxyibonucleotide Binds to the *c-myc* Promoter in HeLa Cells, Thereby Reducing *c-myc* mRNA Levels," *Proc. Natl. Acad. Sci. USA* 88:8227 (1991).	
		POSVIC, et al., "Sequence-Specific Ikylation of Double Helical DNA by Oligonucleotide Directed Triple-Helix Formation," *J. Am. Chem. Soc.* 112:9428 (1992).	
		PRASEUTH, et al., "Sequence-Specific Binding and Photocrosslinking of α and β Oligodeoxynucleotides to the Major Groove of DNA via Triple-Helix Formation," *Proc. Natl. Acad. Sci. USA* 85:1349 (1988).	
		STROBEL, "Site-Specific Cleavage of Human Chromosone 4 Mediated by Triple-Helix Formation," *Science* 254:1639 (1991).	
		TAKASUGI, et al., "Sequence-specific Photo-Induced Cross-Linking of the Two Strands of Double-Helical DNA by a Psoralen Covalently Linked to a Triple Helix Forming Oligonucleotide," *Proceedings of the National Academy of Sciences of USA* 88(13):5602-5606 (1991).	
		UHLMAN, et al., "Antisense Oligonucleotides: A New Therapeutic Principle," *Chem. Reviews* 90(4):544-584 (1990).	
		WOOD, et al., "The Effect of Volume and Temperature on the Energy and Entropy of Pure Liquids," *J. Am. Chem. Soc.* 79:2023 (1957).	
		YOUNG, "Triple Helix Formation Inhibits Transcription Elongation *in vitro*," *Proc. Natl. Sci. USA* 88:10023 (1991).	

Examiner's Signature		Date Considered	10/18/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.